| (Values in U.S. Thousands) | Dec, 2019 | Sep, 2019 | Jun, 2019 | Mar, 2019 | Dec, 2018 |
| Sales | 430 | 250 | 150 | 110 | 200 |
| Sales Growth | +72.00% | +66.67% | +36.36% | -45.00% | +66.67% |
| Net Income | -8,270 | -14,550 | -10,130 | -10,040 | -10,570 |
| Net Income Growth | +43.16% | -43.63% | -0.90% | +5.01% | -42.84% |
Newlink Genetics Cor (NLNK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa.